News for Healthier Living

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidelines define diagnostic criteria, treatment goals and treatment approaches, aiming for progress for people living with IgAN and the clinicians who treat them.

September 26, 2025


October 6 2025

October 5 2025

October 4 2025

October 3 2025

October 2 2025

October 1 2025

September 30 2025

September 29 2025

September 28 2025

September 27 2025

September 26 2025

September 25 2025

September 24 2025

September 23 2025

September 22 2025